HERZLIA, Israel and CALGARY, AB — January 2, 2026 — Leads & Copy — Innocan Pharma Corporation anticipates listing on the NYSE American around January 7, 2026, pending approval of its listing application and compliance with exchange rules.
In conjunction with the anticipated NYSE listing, Innocan is conducting an offering of its securities, subject to market conditions and regulatory approval. Further details will be available through filings with the Securities and Exchange Commission (SEC) and SEDAR+.
Innocan expects its common shares to continue trading on the OTC Markets’ OTCQB until market close on or about January 6, 2026. Upon the NYSE American listing’s effectiveness, trading on the OTCQB will cease. Stockholders do not need to take any action before the NYSE American listing. Innocan’s common shares will continue to trade on the Canadian Securities Exchange (CSE) under the symbol “INNO”.
This announcement is not an offer to buy or sell securities, nor is it a solicitation of an offer. It also does not constitute a solicitation of any vote or approval, nor will there be any sale of securities in any jurisdiction where such actions would be unlawful prior to registration or qualification under securities laws.
Innocan Pharma Corporation is an innovator in the pharmaceuticals and wellness sectors. The company has developed a CBD-loaded liposome drug delivery platform for non-opioid pain management in the pharmaceutical sector. In the wellness sector, Innocan develops and markets self-care and beauty products to promote a healthier lifestyle, conducting business through its 60% owned subsidiary, BI Sky Global Ltd., which focuses on advanced, targeted online sales.
For further information, please contact:
Iris Bincovich, CEO
15162104025+
+972-54-3012842
+442037699377
info@innocanpharma.com
Source: Innocan Pharma Corporation
